Trial · NCT04662060
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| For Clinical Domain: Time-to-sustained-resolution | Placebo | 26 | Inter-Quartile Range 17.5 to NA | days | |
| For Clinical Domain: Time-to-sustained-resolution | Acebilustat | NA | Inter-Quartile Range 22 to NA | days | |
| For the Viral Domain: Change in Viral Shedding | Placebo | 1.6 | 95% Confidence Interval 1.5 to 1.7 | cycles | |
| For the Viral Domain: Change in Viral Shedding | Acebilustat | 1.7 | 95% Confidence Interval 1.6 to 1.7 | cycles | |
| Time to Viral Cessation | Placebo | NA | Inter-Quartile Range NA to NA | days | |
| Time to Viral Cessation | Acebilustat | NA | Inter-Quartile Range NA to NA | days | |
| Time to First Resolution | Placebo | 11.5 | Inter-Quartile Range 7.75 to 18.25 | days | |
| Time to First Resolution | Acebilustat | 14 | Inter-Quartile Range 7 to 18 | days | |
| Time to Full Resolution | Placebo | 13 | Inter-Quartile Range 8.75 to 17.5 | days | |
| Time to Full Resolution | Acebilustat | 15 | Inter-Quartile Range 11 to 18 | days | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Placebo | Hospitalization | 0 | Participants | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Acebilustat | Hospitalization | 1 | Participants | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Placebo | ED visit | 2 | Participants | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Acebilustat | ED visit | 0 | Participants | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Placebo | Death | 0 | Participants | |
| Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease. | Acebilustat | Death | 0 | Participants | |
| Number of Participants That Developed Antibodies to SARS-CoV-2 | Placebo | 55 | Participants | ||
| Number of Participants That Developed Antibodies to SARS-CoV-2 | Acebilustat | 53 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04662060/results